Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Alnylam Pharmaceuticals (Nasdaq: ALNY) announced a company overview presentation at the 10th Annual SVB Leerink Global Healthcare Conference, scheduled for February 25, 2021, at 11:20 am ET. A live audio webcast will be accessible on the Investors section of Alnylam's website, with a replay available 48 hours post-event.

Alnylam is a leader in RNA interference therapeutics, developing innovative medicines for various diseases. Its current products include ONPATTRO, GIVLAARI, and OXLUMO, among others.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 10^th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 11:20 am ET.

A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), and OXLUMO™ (lumasiran), as well as Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005800/en/

FAQ

When will Alnylam Pharmaceuticals present at the SVB Leerink Global Healthcare Conference?

Alnylam Pharmaceuticals will present on February 25, 2021, at 11:20 am ET.

Where can I watch the Alnylam Pharmaceuticals conference presentation?

The presentation can be viewed live on the Investors section of Alnylam's website.

What is the focus of Alnylam Pharmaceuticals?

Alnylam focuses on RNA interference therapeutics for rare genetic and other diseases.

What products does Alnylam Pharmaceuticals currently offer?

Alnylam's products include ONPATTRO, GIVLAARI, and OXLUMO.

Will a replay be available after Alnylam's conference presentation?

Yes, a replay will be available on Alnylam's website within 48 hours after the event.